Determination of rifampicin in human plasma and blood spots by high performance liquid chromatography with UV detection: A potential method for therapeutic drug monitoring

被引:88
作者
Allanson, A. L.
Cotton, M. M.
Tettey, J. N. A.
Boyter, A. C.
机构
[1] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Div Pharmaceut Sci, Glasgow G4 0NR, Lanark, Scotland
[2] Royal Infirm, Dept Resp Med, Glasgow G31 2ER, Lanark, Scotland
关键词
rifampicin; HPLC; dried blood spots; therapeutic drug monitoring; tuberculosis;
D O I
10.1016/j.jpba.2007.04.007
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
A high performance liquid chromatography method has been developed that allows quantification of concentrations of rifampicin in human plasma and blood spots. Rifampicin and papaverine hydrochloride (internal standard) were extracted from plasma using a Strata-X-CW extraction cartridge. These analytes were also extracted into acetonitrile from blood spots dried onto a specimen collection card. The recovery of rifampicin from plasma and blood spots was 84.5% and 65.0%, respectively. Separation was achieved by HPLC on a Kromasil C-18 column with a mobile phase composed of ammonium acetate (20 mM, pH 4.0) and acetonitrile, delivered on a gradient programme. Optimum detection was at 334 nm. The assay was linear over the concentration range of 0.5-20 mu g/ml. The limit of quantification was 0.5 mu g/ml in plasma; 1.5 mu g/ml in blood spots. Both intraday and interday precision data showed reproducibility (R.S.D. <= 8.0, n = 9). Stability studies showed rifampicin was stable in plasma for up to 9 h after thawing; the samples were also stable for up to 9 It after preparation. Five patient samples were analysed using the methods described. A correlation was found between the concentrations of RIF in plasma and blood spots (r(2) = 0.92). This method is proposed as a means of therapeutic drug monitoring of rifampicin in patients with tuberculosis. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:963 / 969
页数:7
相关论文
共 19 条
  • [1] Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels
    Agrawal, S
    Kaur, KJ
    Singh, I
    Bhade, SR
    Kaul, CL
    Panchagnula, R
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2002, 233 (1-2) : 169 - 177
  • [2] [Anonymous], 2005, US PHARM
  • [3] Determination of rifabutin by high-performance liquid chromatography using on-line concentration and column switching
    Bartels, H
    Bartels, R
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 686 (02): : 235 - 240
  • [4] High-performance liquid-chromatographic determination of rifampicin in plasma and tissues
    Calleja, I
    Blanco-Príeto, MJ
    Ruz, N
    Renedo, MJ
    Dios-Viéitez, MC
    [J]. JOURNAL OF CHROMATOGRAPHY A, 2004, 1031 (1-2) : 289 - 294
  • [5] *CDC, CDC GUID SHIPM DRIED
  • [6] Determination of rifabutin in human plasma by high-performance liquid chromatography with ultraviolet detection
    Lau, YY
    Hanson, GD
    Carel, BJ
    [J]. JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1996, 676 (01): : 125 - 130
  • [7] QUANTITATIVE ASSAY OF RIFAMPICIN AND 3 OF ITS METABOLITES IN HUMAN-PLASMA, URINE AND SALIVA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY
    LECAILLON, JB
    FEBVRE, N
    METAYER, JP
    SOUPPART, C
    [J]. JOURNAL OF CHROMATOGRAPHY, 1978, 145 (02): : 319 - 324
  • [8] MANDELL GL, 1995, PRINCIPLES PRACTICE, P318
  • [9] MANDELL GL, 1995, PRINCIPLES PRACTICE, P2226
  • [10] Evaluation of the recently reported USP gradient HPLC method for analysis of anti-tuberculosis drugs for its ability to resolve degradation products of rifampicin
    Mohan, B
    Sharda, N
    Singh, S
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2003, 31 (03) : 607 - 612